Invention Grant
- Patent Title: ADAM12 inhibitors and their use against inflammation-induced fibrosis
-
Application No.: US15690076Application Date: 2017-08-29
-
Publication No.: US10961536B2Publication Date: 2021-03-30
- Inventor: Lucie Peduto , Gerard Eberl
- Applicant: Institut Pasteur
- Applicant Address: FR Paris
- Assignee: Institut Pasteur
- Current Assignee: Institut Pasteur
- Current Assignee Address: FR Paris
- Agency: Arrigo, Lee, Guttman & Mouta-Bellum LLP
- Priority: CA2676946 20090828
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/395 ; C12N15/113 ; A61K38/48 ; G01N33/573 ; G01N33/68 ; A01K67/027 ; C12Q1/6883 ; C12Q1/6897 ; C12N15/85
Abstract:
The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the ablation of ADAM12 expressing cells as therapeutic approach to interfere with the development of pro-fibrotic cells.
Public/Granted literature
- US20170369888A1 ADAM12 Inhibitors and Their Use Against Inflammation-Induced Fibrosis Public/Granted day:2017-12-28
Information query
